REPLICATION AND ONCOGENICITY OF HBV

乙型肝炎病毒的复制和致癌性

基本信息

  • 批准号:
    3172655
  • 负责人:
  • 金额:
    $ 17.57万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1984
  • 资助国家:
    美国
  • 起止时间:
    1984-03-15 至 1992-01-31
  • 项目状态:
    已结题

项目摘要

Hepatitis B virus (HBV) is a major human pathogen, infection with which can lead to the development of cirrhosis and hepatocellular carcinoma. Persistant infection occurs in about 200 million people and is associated with different histological types of chronic liver disease reflecting varying levels of active hepatocyte damage and inflammation. In the last few years, vast amounts of information has accumulated relative to the structure of the virion, the genetic organization and replication of the virus, as well as the transcription and translation of viraal genes. The replicative cycle as well as the pathobiology, including the oncogenicity of HVB, could not be elucidated due to the absence of a tissue culture system in which the virus replicates. However, we succeeded in transfecting HEP G2 cells, derived from a human hepatoblastoma, with HBV DNA. A cell lines was established from these transfected cells which contains integrated and episomal HBV DNA and supports complete HBV replication. The availability of this line should abolish most of the logistic problems encountered so far. It is now experimentally feasible to study: a) the effect of hormones, growth factors, and antiviral agents on the replicaton as well as to idenify liver specific trans- cating factors involved in the replicative cycle; b) the immune response to these cells, which accumulate both surface and core antigens on their membranes; and c) the carcinogenic or co- carcinogenic effect of HBV by injecting these cells into nude mice before or after treatment with carcinogens, or tumor promoters. In addition, the oncogenic potential of HBV will be also studied by transfecting HBV DNA into an "immortalized" human liver cell line obtained by transfecting fetal human liver cells with a plasmid containing SV40 DNA mutated at the origin of replication.
B型肝炎病毒(HBV)是一种主要的人类病原体, 这可能导致肝硬化和肝细胞癌的发展 carcinoma. 持续感染发生在约2亿 人,并与不同的组织类型, 慢性肝病反映了不同水平的活性 肝细胞损伤和炎症。 在过去的几年里, 积累了大量的信息 病毒粒子的遗传组织和复制 病毒,以及病毒基因的转录和翻译。 复制周期和病理学,包括 HVB的致癌性,由于缺乏,无法阐明 病毒在其中复制的组织培养系统。 然而,在这方面, 我们成功地从人源HEP G2细胞中分离出HEP G2细胞, 肝母细胞瘤,HBV DNA。 建立了细胞系 从这些转染的细胞中, 附加型HBV DNA,并支持完整的HBV复制。 的 这条线路的可用性将取消大部分的后勤 目前遇到的问题。 现在,在实验上, 研究:a)激素、生长因子和抗病毒药物的作用 药物的复制,以及使肝脏特异性反式- 参与复制周期的配体因子; B)免疫 对这些细胞的反应,这些细胞积累在表面和核心 抗原;和c)致癌或共- 乙型肝炎病毒对裸鼠的致癌作用 在用致癌物或肿瘤促进剂治疗之前或之后。 此外,还将通过以下方法研究HBV的致癌潜力: 将HBV DNA转染到“永生化”的人肝细胞中 通过用A转染人胎肝细胞获得的细胞系 含有SV 40 DNA的质粒,在 复制的

项目成果

期刊论文数量(14)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Inhibition of the replication of hepatitis B virus by the carbocyclic analogue of 2'-deoxyguanosine.
Expression in Escherichia coli of a cloned DNA sequence encoding the pre-S2 region of hepatitis B virus.
编码乙型肝炎病毒前 S2 区的克隆 DNA 序列在大肠杆菌中的表达。
A nude mouse model for the in vivo production of hepatitis B virus.
用于体内产生乙型肝炎病毒的裸鼠模型。
  • DOI:
    10.1016/0016-5085(90)90840-w
  • 发表时间:
    1990
  • 期刊:
  • 影响因子:
    29.4
  • 作者:
    Zhai,WR;Vajta,G;Acs,G;Paronetto,F
  • 通讯作者:
    Paronetto,F
Enzyme-linked immunoassay of pre-S gene-coded sequences in hepatitis B vaccines.
乙型肝炎疫苗中前 S 基因编码序列的酶联免疫分析。
  • DOI:
    10.1016/0166-0934(85)90128-4
  • 发表时间:
    1985
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    Neurath,AR;Strick,N;Kent,SB;Offensperger,W;Wahl,S;Christman,JK;Acs,G
  • 通讯作者:
    Acs,G
Tumor necrosis factor-alpha induces a kappa B sequence-specific DNA-binding protein in human hepatoblastoma HepG2 cells.
肿瘤坏死因子-α 在人肝母细胞瘤 HepG2 细胞中诱导 kappa B 序列特异性 DNA 结合蛋白。
  • DOI:
    10.1002/hep.1840100620
  • 发表时间:
    1989
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Banerjee,R;Karpen,S;Siekevitz,M;Lengyel,G;Bauer,J;Acs,G
  • 通讯作者:
    Acs,G
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GEORGE ACS其他文献

GEORGE ACS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GEORGE ACS', 18)}}的其他基金

STUDIES ON THE REPLICATION AND ONCOGENICITY OF HBV
乙型肝炎病毒的复制和致癌性研究
  • 批准号:
    3172651
  • 财政年份:
    1984
  • 资助金额:
    $ 17.57万
  • 项目类别:
REPLICATION AND ONCOGENICITY OF HBV
乙型肝炎病毒的复制和致癌性
  • 批准号:
    3172654
  • 财政年份:
    1984
  • 资助金额:
    $ 17.57万
  • 项目类别:
STUDIES ON THE REPLICATION AND ONCOGENICITY OF HBV
乙型肝炎病毒的复制和致癌性研究
  • 批准号:
    3172648
  • 财政年份:
    1984
  • 资助金额:
    $ 17.57万
  • 项目类别:
STUDIES ON THE REPLICATION AND ONCOGENICITY OF HBV
乙型肝炎病毒的复制和致癌性研究
  • 批准号:
    3172653
  • 财政年份:
    1984
  • 资助金额:
    $ 17.57万
  • 项目类别:
STUDIES ON THE REPLICATION AND ONCOGENICITY OF HBV
乙型肝炎病毒的复制和致癌性研究
  • 批准号:
    3172652
  • 财政年份:
    1984
  • 资助金额:
    $ 17.57万
  • 项目类别:
STUDIES ON CHEMOTHERAPEUTIC DEOXYRIBONUCLEOSIDES
化疗脱氧核糖核苷的研究
  • 批准号:
    3164560
  • 财政年份:
    1977
  • 资助金额:
    $ 17.57万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 17.57万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 17.57万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 17.57万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 17.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 17.57万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 17.57万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 17.57万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 17.57万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 17.57万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 17.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了